Predictive Oncology — an oncology drug development and research company that uses Artificial Intelligence and machine learning — announced that they are moving their corporate headquarters to Pittsburgh, from Eagan, Minnesota.

“We could have chosen to go anywhere,” said Raymond F. Vennare, Predictive Oncology’s chief executive officer and chairman of the board. “We chose to be in Pittsburgh because it is one of the most important cities, I think, in the country when it comes to innovation and technology commercialization and that’s been the impetus for doing this.”

The company has multiple locations around the country, but decided to move its main operations to Pittsburgh to have better access to institutions leading the way in AI development and bioinformatics such as Carnegie Mellon University, the University of Pittsburgh and UPMC, Mr. Vennare said.

The relocation follows a recent expansion at the company’s Pittsburgh research lab where Predictive Oncology recently extended their five-year-lease on a 20,000-square-foot space in Lawrenceville. The lab is located at the Regional Industrial Development Corporation’s “Old Chocolate Factory” on 43rd street.

Advertise with us

“It’s about having access to Lawrenceville, Oakland and Shadyside where scientists and engineers reside,” Mr. Vennare said.

The move to Pittsburgh, which is now recognized as a leading tech hub, should facilitate business relationships on a global scale. For example, Mr. Vennare said, Predictive Oncology is now working in partnership with Cancer Research Horizons — a company based in the United Kingdom — that is one of the world’s largest private funders of cancer and drug research.

“By virtue of that relationship, we now have a global presence,” Mr. Vennare said. “They have relationships with major pharmaceutical companies and I am looking forward to bringing that business to Pittsburgh.”

The company hopes that the move here also will help further the application of artificial intelligence for drug discovery.

“That domain expertise and the kind of people that you need to do that requires not only artificial intelligence and machine learning, but also an understanding of computational biology, bioinformatics and clinical services,” Mr Vennare said. “And all of that is literally within a mile or two of our laboratory.”

Ciara McEneany: cmceneany@post-gazette.com